No abstract

Continuous processing for the production of monoclonal antibodies (mAb) gains more and more importance. Several solutions exist for all the necessary production steps, leading to the possibility to build fully continuous processes. Low pH viral inactivation is a part of the standard platform process for mAb production. Consequently, Klutz et al. introduced the coiled flow inverter (CFI) as a tool for continuous low pH viral inactivation. Besides theoretical calculations of viral reduction, no viral clearance study has been presented so far. In addition, the validation of continuous viral clearance is often neglected in the already existing studies for continuous processing. This study shows in detail the development and execution of a virus study for continuous low pH viral inactivation inside a CFI. The concept presented is also valid for adaptation to other continuous viral clearance steps. The development of this concept includes the technical rationale for an experimental setup, a valid spiking procedure, and finally a sampling method. The experimental results shown represent a viral study using xenotropic murine leukemia virus as a model virus. Two different protein A (ProtA) chromatography setups with varying pH levels were tested. In addition, one of these setups was tested against a batch experiment utilizing the same process material. The results show that sufficient low pH viral inactivation (decadic logarithm reduction value >4) was achieved in all experiments. Complete viral inactivation took place within the first 14.5 min for both continuous studies and the batch study, hence showing similar results. This study therefore represents a successful virus study concept and experiment for a continuous viral inactivation step. Moreover, it was shown that the transfer from batch results to the continuous process is possible. This is accomplished by the narrow residence time distribution of the CFI, showing how close the setup approaches the ideal plug flow and with that batch operation. Biotechnology and Bioengineering. 2019;116:857-869. wileyonlinelibrary.com/journal/bit Symbols: d, decadic logarithm of the serial dilution steps; D, sample predilution; n, total number of analyzed cell culture wells; n p , number of virus-positive wells; p, probability value; P i , summation of virus-positive cell cultures within the virus transition area; R w , relative width; v, decadic logarithm of the volume conversion factor; V, overall volume of the virus-containing sample; V w , analyzed sample volume; Y 0 , decadic logarithm of the highest dilution of the virus-containing sample; Θ 0.005 , dimensionless time point where 0.5% of the maximum dimensionless concentration is reached; Θ 0.995 , dimensionless time point where 99.5% of the maximum dimensionless concentration is reached. K E Y W O R D S coiled flow inverter, continuous processing, low pH, monoclonal antibodies, viral inactivation

Continuous processing is the future production method for monoclonal antibodies (mAbs). A fully continuous, fully automated downstream process based on disposable equipment was developed and implemented inside the MoBiDiK pilot plant. However, a study evaluating the comparability between batch and continuous processing based on product quality attributes was not conducted before. The work presented fills this gap comparing both process modes experimentally by purifying the same harvest material (side‐by‐side comparability). Samples were drawn at different time points and positions in the process for batch and continuous mode. Product quality attributes, product‐related impurities, as well as process‐related impurities were determined. The resulting polished material was processed to drug substance and further evaluated regarding storage stability and degradation behavior. The in‐process control data from the continuous process showed the high degree of accuracy in providing relevant process parameters such as pH, conductivity, and protein concentration during the entire process duration. Minor differences between batch and continuous samples are expected as different processing conditions are unavoidable due to the different nature of batch and continuous processing. All tests revealed no significant differences in the intermediates and comparability in the drug substance between the samples of both process modes. The stability study of the final product also showed no differences in the stability profile during storage and forced degradation. Finally, online data analysis is presented as a powerful tool for online‐monitoring of chromatography columns during continuous processing.

No abstract

No abstract